Eligo Bioscience

Eligo | In vivo gene editing of the microbiome

Paris, France · Founded 2014 · $57.5M raised

Headquarters
Paris
Employees
11–50
Founded
2014
Business Model
B2B
Website
eligo.bio
Total Funding
$57.5M
Last Round
$5.0M GrantMay 2025
Rounds
4

About

Eligo Bioscience is a clinical-stage biotechnology company developing in vivo gene editing medicines that precisely target the microbiome. Their proprietary GEM (Gene Editing of the Microbiome) platform uses phage-derived delivery systems to edit bacterial genes inside the body, enabling precision treatment of diseases in oncology, inflammation, and autoimmunity driven by specific microbial gene expression.

Summary

Eligo Bioscience is a Biotech company based in Paris, France, founded in 2014. It has raised $57.5M in total across 4 rounds, most recently a $5.0M Grant round in May 2025. Investors include Seventure Partners, Khosla Ventures and CARB-X.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

GrantMay 2025
$5.0M

Sign up to see all 4 rounds

Seed through Grant — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Eligo Bioscience on Indexed.vc
<a href="https://indexed.vc/companies/eligo-bioscience"><img src="https://indexed.vc/api/badge/company/eligo-bioscience" alt="Eligo Bioscience on Indexed.vc" width="260" height="76" /></a>